Genentech, a member of the Roche Group, announced on Sunday that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted a priority review for the company’s obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for patients who have previously untreated follicular lymphoma.
Genentech, a member of the Roche Group, announced on Sunday that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted a priority review for the company’s obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for patients who have previously untreated follicular lymphoma.
The sBLA for obinutuzumab is based on the GALLIUM study, which demonstrated that treatment with the drug significantly improved progression-free survival (PFS) over rituximab-based treatment, the current standard of care.
The study, a global, phase 3, open-label, multicenter, randomized, 2-arm study, provided a head-to-head comparison with rituximab (also Genentech’s drug) plus chemotherapy, followed by rituximab alone, for up to 2 years. The GALLIUM study included 1401 patients with previously untreated indolent non-Hodgkin’s lymphoma, 1202 of whom had follicular lymphoma. The study’s primary endpoint was PFS in patients with follicular lymphoma (assessed by an investigator). Secondary endpoints included PFS as assessed by an independent review committee.
Results after the follow-up period of 41.1 months showed that obinutuzumab-based treatment reduced the risk of disease worsening or death by 32% (investigator assessment) or 28% (independent review committee assessment) compared to rituximab-based treatment.
The most common grade 3 to 5 adverse events that occurred more often with obinutuzumab than with rituximab were the following:
The drug maker says that it expects the FDA to make a decision on approval of the proposed indication by December 23, 2017. Roche has been focusing on the development of innovator drugs as it faces looming biosimilar competition for market share of its top 3 cancer drugs, bevacizumab (Avastin), trastuzumab (Herceptin), and rituximab (Mabthera, Rituxan), which jointly earned Roche $22.1 billion in sales in 2016.
News of obinutuzumab’s priority review follows another such announcement from Genentech on Wednesday; last week, the drug maker announced that the FDA had accepted a BLA and granted priority review for its emicizumab, a novel biologic for the treatment of hemophilia A in patients who have factor VIII inhibitors.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
January 16th 2025Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, showcasing notable pricing trends and market share disparities across therapeutic areas.